When was AmplifyBio founded?

AmplifyBio was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is AmplifyBio located?

AmplifyBio is headquartered in Hilliard, United States.

How many employees does AmplifyBio have?

As of Apr 06, 2025, the latest employee count at AmplifyBio is 188.

Is AmplifyBio a funded company?

AmplifyBio is a funded company, having raised a total of $230M across 4 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on May 22, 2021.

When was the latest funding round of AmplifyBio?

AmplifyBio's latest funding was a $***** Series C round on Oct 31, 2023, with participation from 0 investor. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $902M in funding in 2026 to date.

Where does AmplifyBio rank among its competitors?

AmplifyBio ranks 23rd amongst 377 active competitors, of which 42 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Acclinate, which secured $3.5M in Feb, 2026.

Who are the top competitors of AmplifyBio?

AmplifyBio's top competitors include Novartis, Catalent and WuXi Biologics. Among them, Acclinate secured the most recent funding round in February, 2026.

AmplifyBio - 2026 Company Profile, Funding & Competitors

AmplifyBio is a deadpooled company based in Hilliard (United States), founded in 2021. It operates as a Provider of contract research, development, and manufacturing services for biologic drugs. AmplifyBio has raised $230M in funding. The company has 377 active competitors, including 42 funded and 53 that have exited. Its top competitors include companies like Novartis, Catalent and WuXi Biologics.

Company Details

Website: amplify-bio.com
Social

Key Metrics

Founded Year

2021

Location

Hilliard, United States

Stage

Deadpooled

Total Funding

$230M in 4 rounds

Latest Funding Round

Series C, Oct 31, 2023, $*****

Investors

Hercules Capital & 1 more

Ranked

23^rd among 377 active competitors

Employee Count

188 as on Apr 06, 2025

Similar Companies

Novartis & 430 more

View AmplifyBio's full profile

AmplifyBio has raised a total funding of $230M over 4 rounds. Its first funding round was on May 22, 2021. AmplifyBio has 2 institutional investors.

Here is the list of recent funding rounds of AmplifyBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 31, 2023	8552001	Series C	9205306	4245872	5180551	8958402
Jan 12, 2023	3721048	Venture Debt	9939167	8285206	2833078	Hercules Capital
Apr 30, 2022	1465709	Series C	7441196	8119149	9643659	6791906

Access funding benchmarks and valuations. Sign up today!

View details of AmplifyBio's funding rounds and investors

AmplifyBio's employee count trend

AmplifyBio has 188 employees as of Apr 25. Here is AmplifyBio's employee count trend over the years:

Uncover AmplifyBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AmplifyBio include Novartis, Catalent and WuXi Biologics. Here is the list of Top 10 competitors of AmplifyBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	72/100
2nd	Catalent 2007, Somerset (United States), Acquired	Provider of development, manufacturing, and packaging solutions for medicines and supplements	-	Aisling Capital, JPMorgan Chase & 5 others	68/100
3rd	WuXi Biologics 2008, Shanghai (China), Public	Developer and manufacturer for protein therapeutics	-	Pivotal bioVenture Partners, HongShan & 3 others	55/100
4th	Curia 1991, Albany (United States), Acquired	Provider of drug research & development, testing, and consulting services	-	HarbourVest Partners, Thecarlylegroup.fr & 6 others	53/100
5th	Acclinate 2020, Birmingham (United States), Series A	Provider of clinical trial services to biopharma sector	$15.5M	Cencora, Alabama Launchpad & 7 others	51/100
6th	Ventus Therapeutics 2019, Boston (United States), Series C	Develops small‑molecule therapeutics for autoimmune and auto‑inflammatory diseases treatment	$300M	RA Capital Management, Versant Ventures & 11 others	51/100
7th	BioFactura 2004, Frederick (United States), Series B	Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs	$7.8M	Wilson Sonsini Goodrich & Rosati, UVM Health ... & 2 others	51/100
8th	TCI 1980, Taipei (Taiwan), Public	Manufacturer of functional foods and dietary supplements	-	JAFCO Asia, Japan Asia Investment	49/100
9th	Biotage 1989, Uppsala (Sweden), Acquired	Organic synthesis, analytical, and peptide chemistry services for drug discovery and development	-	Taaleri, Investor Growth Capital & 4 others	49/100
10th	Sunflower Therapeutics 2018, Hingham (United States), Series A	Provider of drug development & research services for multiple therapeutic areas	$5.64M	NIAID, Clear Current Capital & 3 others	48/100
23rd	AmplifyBio 2021, Hilliard (United States), Deadpooled	Provider of contract research, development, and manufacturing services for biologic drugs	$230M	Hercules Capital, Casdin Capital	42/100